SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival
You may also be interested in...
MGI Submits Saforis NDA: Pipeline To Propel Sales To $1 Bil. By 2010 – Firm
MGI Pharma’s recently submitted oral mucositis therapy Saforis and newly approved myelodysplastic syndromes agent Dacogen top a "deep and maturing pipeline" projected to drive corporate sales to $1 bil. by 2010, according the company.
SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal
SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011